Zhang Mengru, Morice Alyn H, Si Fengli, Zhang Li, Chen Qiang, Wang Shengyuan, Zhu Yiqing, Xu Xianghuai, Yu Li, Qiu Zhongmin
Department of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Centre for Clinical Science, Respiratory Medicine, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham, East Yorkshire, UK.
Allergy Asthma Immunol Res. 2023 Nov;15(6):795-811. doi: 10.4168/aair.2023.15.6.795.
PURPOSE: Only limited studies have depicted the unique features and management of refractory chronic cough (RCC) and unexplained chronic cough (UCC). These led to the initiation of this study, which reported the demographic characteristics, manifestations, and long-term outcomes on a large series of consecutive RCC/UCC patients, providing a guideline-led real-world clinical experience. METHODS: Retrospective baseline information was obtained from Clinical Research Database (January 2016 to May 2021). At least 6 months after the last clinic visit, included subjects were prospectively followed up. RESULTS: Three hundred and sixty-nine RCC and UCC patients (199 females, 53.9%) were analyzed. The median cough duration was 24.0 (12.0-72.0) months. Laryngeal symptoms were reported in 95.9% of the patients. The common triggers for coughing were talking (74.9%), pungent odors (47.3%), eating (45.5%), and cold air (42.8%). RCC was considered in 38.2%, and the remainder of 228 patients had UCC, with an equal sex distribution ( = 0.66). Among the 141 RCCs, 90.8% (128) had refractory reflux cough, which was more responsive to current treatments ( < 0.01). Although most features and test results between RCC and UCC were similar, UCC was more commonly inappropriately treated ( < 0.01). Nineteen (7.7-41.1) months after the final clinic visit, 31.2% still coughed persistently, while 68.8% reported cough improvement or remission. RCC reported more favorable treatment outcomes (including cough improvement, control, and spontaneous remission) than UCC ( < 0.01). Coughs with long duration before the initial cough clinic visit ( < 0.01), frequent urinary incontinence ( < 0.01), and being sensitive to "talking" ( < 0.01) or "cold air" ( < 0.01) were less likely to be solved. CONCLUSIONS: The current treatments only improve cough symptoms in two-thirds of patients. Clinical indicators for treatment failure were those coughing for long duration and being sensitive to "talking" or "cold air."
目的:仅有有限的研究描述了难治性慢性咳嗽(RCC)和不明原因慢性咳嗽(UCC)的独特特征及管理方法。这些研究促使开展本项研究,该研究报告了一大系列连续的RCC/UCC患者的人口统计学特征、临床表现及长期结局,提供了以指南为导向的真实世界临床经验。 方法:从临床研究数据库(2016年1月至2021年5月)获取回顾性基线信息。在最后一次门诊就诊至少6个月后,对纳入的受试者进行前瞻性随访。 结果:分析了369例RCC和UCC患者(199例女性,占53.9%)。咳嗽持续时间的中位数为24.0(12.0 - 72.0)个月。95.9%的患者报告有喉部症状。咳嗽的常见诱发因素为说话(74.9%)、刺激性气味(47.3%)、进食(45.5%)和冷空气(42.8%)。38.2%的患者被诊断为RCC,其余228例患者为UCC,性别分布均衡(P = 0.66)。在141例RCC患者中,90.8%(128例)患有难治性反流性咳嗽,对当前治疗反应更好(P < 0.01)。尽管RCC和UCC之间的大多数特征和检查结果相似,但UCC更常接受不恰当的治疗(P < 0.01)。在最后一次门诊就诊19(7.7 - 41.1)个月后,31.2%的患者仍持续咳嗽,而68.8%的患者报告咳嗽有所改善或缓解。RCC患者报告的治疗效果(包括咳嗽改善、控制和自发缓解)优于UCC(P < 0.01)。初次咳嗽门诊就诊前咳嗽持续时间长(P < 0.01)、频繁尿失禁(P < 0.01)以及对“说话”(P < 0.01)或“冷空气”(P < 0.01)敏感的咳嗽更难治愈。 结论:目前的治疗仅能使三分之二的患者咳嗽症状得到改善。治疗失败的临床指标是咳嗽持续时间长以及对“说话”或“冷空气”敏感。
Allergy Asthma Immunol Res. 2023-11
Ther Adv Respir Dis. 2024
ERJ Open Res. 2021-3-29
BMC Pulm Med. 2022-11-19
Am J Respir Crit Care Med. 2025-6
Curr Opin Otolaryngol Head Neck Surg. 2024-12-1
ERJ Open Res. 2022-7-25
Eur Respir Rev. 2021-12-31
Zhonghua Jie He He Hu Xi Za Zhi. 2021-8-12
Int J Tuberc Lung Dis. 2021-8-1
Ann Am Thorac Soc. 2021-12